FindTrial
Sign In

COMPARATIVE EVALUATION OF NEW MUSCLE RELAXANTS IN PATIENTS UNDERGOING ABDOMINAL LAPAROSCOPIC SURGERIES

COMPARATIVE EVALUATION OF CISATRACURIUM AND ATRACURIUM IN PATIENTS UNDERGOING ABDOMINAL LAPAROSCOPIC SURGERIES - cisatracurium

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017371
Enrollment
50
Registered
2019-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: cisatracurium: 3xED95 dose of cisatracurium. 0.15mg/kg via intravenous route Control Intervention1: atracurium: 3xED95 dose of atracurium. 0.6mg/kg via intravenous route

Sponsors

Fortis Memorial Research Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA I ASA II

Exclusion criteria

Exclusion criteria: 1.Patients refusing to participate in study 2.Patient with neuromuscular diseases 3.Patient taking aminoglycosides, tetracycline 4.Anticipated difficult intubation 5.Patients requiring Rapid Sequence Induction 6.Pregnancy 7.Obese individuals ( BMI > 35) 8.Patients with asthma, atopy and allergic tendencies 9.Patient requiring Emergency surgery

Design outcomes

Primary

MeasureTime frame
compare clinical profile of cisatracurium and atracuriumTimepoint: 1. onset 2. intubating conditions 3. duration of action 4. recovery—

Secondary

MeasureTime frame
side effectsTimepoint: within first 10 minutes of intubating dose—

Countries

India

Contacts

Public ContactDr Rohit Bhandari

fortis memorial research institute

hari.dash@fortishealthcare.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026